Topotecan in patients with advanced neuroendocrine tumors: A phase II study with significant hematologic toxicity

Stephen M. Ansell, Michelle R. Mahoney, Erin M. Green, Joseph Rubin

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

New agents with antitumor activity in neuroendocrine tumors are sorely needed. We therefore conducted a phase II study of topotecan (TOPA) 1.5 mg/m2/d for 5 days every 3 weeks in 22 patients with advanced carcinoid and islet cell tumors. Severe neutropenia in 8 of 11 patients (72%) prompted a 30% dose reduction of TOPA to 1.05 mg/m2 for the final 11 patients enrolled. No objective responses were observed. Eighteen patients have progressed and 14 have died. The median time to progression was 4.2 months (95% CI: 2.9-6.5) and the median survival was 1.9 years (95% CI: 0.63-2.3). Hematologic adverse events were significant, with 16 of 22 patients developing grade IV neutropenia; however, there were no septic deaths. Nonhematologic adverse events were infrequent and were not dose limiting. In conclusion, further studies of this schedule of TOPA in this patient population are not recommended due to the lack of tumor response and significant hematologic toxicity.

Original languageEnglish (US)
Pages (from-to)232-235
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume27
Issue number3
DOIs
StatePublished - Jun 1 2004

Keywords

  • Carcinoid tumor
  • Islet cell tumor
  • Neuroendocrine tumors
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Topotecan in patients with advanced neuroendocrine tumors: A phase II study with significant hematologic toxicity'. Together they form a unique fingerprint.

  • Cite this